Eczacıbaşı-Monrol

Monrol is a global radiopharmaceutical company dedicated to serving patients worldwide.​

Founded in 1995 and headquartered in Istanbul, Turkey, Monrol specialises in the development and manufacturing of Good Manufacturing Practice (GMP) grade radioisotopes and radiopharmaceuticals. The company distributes its diverse portfolio to over 70 countries, operating 13 facilities across the globe. With a workforce exceeding 300 employees, Monrol is recognised as one of the largest producers of Lutetium-177, a radioisotope pivotal in targeted cancer therapies. ​

Key Products and Services:

Theranostic Products: High-specific-activity and high-purity products used in both diagnosis and treatment, embodying the theranostic approach in nuclear medicine.​

Radiopharmaceutical Supply Expertise: Comprehensive services ensuring the reliable provision of radiopharmaceuticals to healthcare providers and patients globally.​

Logistics Network Excellence: A robust distribution network delivering to over 70 locations, ensuring timely and efficient product availability.​

Contract Development and Manufacturing Organisation (CDMO) Services: Tailored solutions and services for drug development, supporting partners from concept through to clinical trials. ​

In alignment with its commitment to innovation and patient care, Monrol announced plans in September 2022 to establish a legal entity and manufacturing facility in Germany. This new site will focus on producing Single Photon Emission Computed Tomography (SPECT) products and radiopharmaceuticals for radioligand therapy, including Gallium-68 generators and non-carrier-added (n.c.a) Lutetium-177. The facility will also offer state-of-the-art cGMP CDMO services, further enhancing Monrol's capacity to support advancements in cancer treatment.